A small Tigard firm signed a deal with Bausch + Lomb for an eye-dilation product.
A small Tigard firm signed a deal with Bausch + Lomb for an eye-dilation product.
The product, called phenylephrine hydrochloride ophthalmic solution, was already in use by opthamologists and sold by Bausch + Lomb. However, it existed in a legal gray area of products that had never gone through the formal federal drug approval process.
Patrick Witham, President and CEO of Paragon BioTeck, Inc., submitted a drug approval request for the product in late 2012. Last month, the Food and Drug Administration approved Paragon’s application, giving his firm sole right to market the drug.
Read more at OregonLive.com.
{biztweet}tigard bausch + lomb{/biztweet}
